Zoetis Inc. (ZTS)
After hours:
| Previous close | 201.96 |
| Open | 203.11 |
| Bid | 198.00 x 900 |
| Ask | 200.25 x 1000 |
| Day's range | 200.28 - 203.71 |
| 52-week range | 141.41 - 249.27 |
| Volume | |
| Avg. volume | 1,780,338 |
| Market cap | 94.781B |
| Beta (5Y monthly) | 0.66 |
| PE ratio (TTM) | 48.28 |
| EPS (TTM) | 4.15 |
| Earnings date | 15 Feb 2022 |
| Forward dividend & yield | 1.30 (0.65%) |
| Ex-dividend date | 19 Jan 2022 |
| 1y target est | 248.83 |
- Motley Fool
2 Stocks That Could Turn $250,000 Into $1,000,000 By 2032
Let's look at two excellent companies that could turn $250,000 into $1,000,000 -- that's a compound annual growth rate of 14.87% -- in the next 10 years: Zoetis (NYSE: ZTS) and Spotify (NYSE: SPOT). Zoetis is one of the leading animal health companies in the world. Zoetis boasts 13 products that generate $100 million or more in annual revenue, and its financial results continue to impress.
- Business Wire
Zoetis Announces FDA Approval of Solensia™ (frunevetmab injection) to Control Osteoarthritis Pain in Cats
PARSIPPANY, N.J., January 13, 2022--Zoetis today announced that the U.S. Food and Drug Administration (FDA) has approved Solensia™ to control the pain of osteoarthritis (OA) in cats.
- Motley Fool
Why Zoetis Stock Gained 47% in 2021
Shares of Zoetis (NYSE: ZTS) had a strong 2021 as the animal health company posted solid growth throughout the year and consistently raised its guidance. Zoetis shares slumped through the first two months of the year as a solid fourth-quarter 2020 earnings report wasn't enough to give the stock a boost.
